GeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 Honoree
GAITHERSBURG, Md.--(BUSINESS WIRE)--Katherine Stueland, CEO of GeneDx, has been named a 2026 Fierce 50 honoree for Health Equity.
WGS - GeneDx Holdings Corp.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$79.50
DETAILS
HIGH:
$90.00
LOW:
$63.00
MEDIAN:
$80.00
CONSENSUS:
$79.50
DOWNSIDE:
7.55%
Stock News
GeneDx Holdings Corp (WGS) Shares Surge 3.3% -- What GF Score of 65 Tells Investors
On August 26, 2026, GeneDx Holdings Corp (WGS) shares rose 3.3%, bringing the current price to $90.28. The stock is trading within a 52-week range of $32.21 to
Short Sellers Are All-In on These 10 Stocks — Squeeze Watch List Inside
Bears have piled into a familiar batch of volatile, heavily bet-against names, and nowhere is the wager bigger than on Venture Global, Inc. (NYSE:VG). More than 80% of its float is sold short, the steepest ratio on the market's current top-10 short-interest list, per Benzinga Pro data.
GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children's
[url="]GeneDx[/url] (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced new data publish
GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children's
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx and Seattle Children's show hospital-wide rapid genome sequencing accelerates accurate diagnosis and expands access to answers for children.
Can GENEDX HOLDINGS (WGS) Run Higher on Rising Earnings Estimates?
GeneDx Holdings Corp. (WGS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
GeneDx: Why I Think The Worst Is Behind The Business
GeneDx shows early signs of operational recovery, with Q2 revenue and margins exceeding expectations and testing volumes up 32%. Reimbursement rates have stabilized, and management expects meaningful improvements in Q4 and a stronger recovery in 2027. Valuation remains attractive, with a Buy rating maintained. Upside potential exists if reimbursement and growth targets are met.
Is GeneDx Holdings Corp (WGS) Overvalued After 5.1% Rally? GF Value Says Overvalued
On August 11, 2026, GeneDx Holdings Corp (WGS) shares rose 5.1% to $81.83, bouncing back in a volatile market. Over the past 52 weeks, the stock has traded betw
GeneDx Launches New Online Offering for Families to Improve Accessibility of Exome Testing for Children with Global Developmental Delay, Intellectual Disability and Epilepsy
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx launches a new online offering to expand access to exome testing and help more children and families get answers sooner.
GeneDx Holdings Corp. $WGS Shares Acquired by Dimensional Fund Advisors LP
Dimensional Fund Advisors LP boosted its position in GeneDx Holdings Corp. (NASDAQ: WGS) by 143.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 265,791 shares of the company's stock after buying an additional 156,603 shares during the quarter. Dimensional
GeneDx to Participate in Upcoming Investor Conferences
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) announced that company management will participate in the Canaccord Genuity and Wells Fargo investor conferences.
GeneDx Holdings Corp. (WGS) Q2 2026 Earnings Call Transcript
GeneDx Holdings Corp. (WGS) Q2 2026 Earnings Call Transcript
GeneDx Q2 Earnings Call Highlights
GeneDx NASDAQ: WGS reported second-quarter revenue of $114.4 million, above its prior guidance, as exome and genome testing volume reached a quarterly record of more than 30,000 tests. The company also returned to adjusted profitability one quarter earlier than previously expected, while maintaining its full-year 2026 outlook.
GeneDx Holdings Corp. (WGS) Q2 Earnings and Revenues Surpass Estimates
GeneDx Holdings Corp. (WGS) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.19 per share. This compares to earnings of $0.5 per share a year ago.
GeneDx Reports Second Quarter 2026 Financial Results
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today reported its financial and operational results for the second quarter of 2026.
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds GeneDx (WGS) Investors of Securities Class Action Lawsuit Deadline on August 3, 2026
[url="]Faruqi and Faruqi, LLP[/url], a leading national securities law firm, is investigating potential claims against GeneDx Holdings Corp. (âGeneDxâ or the
Bronstein, Gewirtz & Grossman LLC Urges GeneDx Holdings Corp. Investors to Act: Class Action Filed Alleging Investor Harm
New York, New York--(Newsfile Corp. - August 3, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against GeneDx Holdings Corp. (NASDAQ: WGS) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired GeneDx securities between April 16, 2025 and May 4, 2026, both dates inclusive (the "Class Period").
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds GeneDx (WGS) Investors of Securities Class Action Lawsuit Deadline on August 3, 2026
NEW YORK--(BUSINESS WIRE)---- $WGS #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ: WGS) and reminds investors of the August 3, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm h.
WGS Investors Have Opportunity to Lead GeneDx Holdings Corp. Securities Fraud Lawsuit with SBS Law
LOS ANGELES, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GeneDx Holdings Corp. (“GeneDx” or “the Company”) (NASDAQ: WGS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of WGS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.
DEADLINE TODAY: GeneDx Holdings Corp. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - WGS
LOS ANGELES, Aug. 3, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against GeneDx Holdings Corp. ("GeneDx" or "the Company") (NASDAQ: WGS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of WGS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.
Price Targets
GeneDx (WGS) PT Raised to $90 at Canaccord
$90.00
(was $67.86)
Kyle Mikson
·
Canaccord Genuity
GeneDx price target raised to $74 from $70 at Guggenheim
$74.00
(was $69.82)
Guggenheim
GeneDx price target raised to $63 from $50 at Piper Sandler
$63.00
(was $55.42)
David Westenberg
·
Piper Sandler
GeneDx price target lowered to $85 from $153 at Craig-Hallum
$85.00
(was $35.59)
Bill Bonello
·
Craig-Hallum
GeneDx price target lowered to $90 from $170 at BTIG, removed from Top Picks
$90.00
(was $67.93)
BTIG
GeneDx price target lowered to $70 from $100 at Guggenheim
$70.00
(was $67.93)
Guggenheim
GeneDx price target lowered to $75 from $100 at Canaccord
$75.00
(was $67.93)
Kyle Mikson
·
Canaccord Genuity
GeneDx price target lowered to $75 from $155 at Wells Fargo
$75.00
(was $67.93)
Brandon Couillard
·
Wells Fargo
GeneDx price target raised to $100 from $70 at Canaccord
$100.00
(was $67.72)
Canaccord Genuity
GeneDx price target lowered to $170 from $200 at BTIG
$170.00
(was $87.08)
Mark Massaro
·
BTIG
GeneDx price target lowered to $130 from $160 at Piper Sandler
$130.00
(was $87.08)
David Westenberg
·
Piper Sandler
GeneDx price target lowered to $150 from $180 at Jefferies
$150.00
(was $87.08)
Jefferies
GeneDx price target raised to $170 from $160 at Canaccord
$170.00
(was $140.44)
Canaccord Genuity
GeneDx price target raised to $155 from $140 at Wells Fargo
$155.00
(was $151.37)
Wells Fargo
GeneDx price target raised to $200, named 2026 Top Pick at BTIG
$200.00
(was $155.36)
BTIG
GeneDx price target raised to $165 from $140 at BTIG
$165.00
(was $137.40)
BTIG
GeneDx price target raised to $160 from $155 at Canaccord
$160.00
(was $137.47)
Canaccord Genuity
GeneDx price target raised to $170 from $115 at Guggenheim
$170.00
(was $137.47)
Guggenheim
GeneDx initiated with a Buy at Canaccord
$155.00
(was $120.94)
Canaccord Genuity
GeneDx price target raised to $120 from $110 at Piper Sandler
$120.00
(was $108.35)
Piper Sandler